Gabapentin Tablet, Film Coated
Product Images NDC 43063-611

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 43063-611). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063611 Label (43063611)

Label for Gabapentin USP 800 mg tablets, film-coated, oral use, containing 90 tablets. The product is labeled by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK, with NDC 43063-611-90. The label includes dosage and storage warnings, reorder number, lot, and expiration information, along with instruction placeholders for dosage directions in English and Spanish.*

FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 01

A formula expressed in text showing creatinine clearance (CLCr) calculation. The formula is the product of (140 minus age in years) and weight in kilograms, divided by 72 times serum creatinine in mg/dL, with a multiplication factor of 0.85 for female patients. This formula is typically used to estimate renal function.*

FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 02

Chemical structure of gabapentin, showing the molecular arrangement including a cyclohexane ring bonded to amino and carboxymethyl groups.*

FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 03

A line graph depicting mean pain score over an 8-week period, comparing placebo and gabapentin 3600 mg/day. The x-axis shows weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis represents mean pain score from 0 to 10, with gabapentin showing a decline in pain scores compared to placebo.*

FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 04

A line graph showing mean pain scores over 7 weeks for placebo and two Gabapentin dose groups (1800 mg/day and 2400 mg/day). The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period. Gabapentin groups show decreased pain scores compared to placebo over time.*

FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 05

A bar graph comparing two studies on treatment effects. The x-axis shows treatment groups: Placebo (PBO) and Gabapentin (GBP) at doses 1800, 2400, and 3600 mg. The y-axis indicates percentage outcomes from 0% to 100%. Study 1 compares PBO and GBP 3600 mg, showing 12% and 29% respectively, with statistical significance. Study 2 compares PBO, GBP 1800 mg, and GBP 2400 mg, showing 14%, 32%, and 34% respectively, also with statistical significance noted.*

FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 06

A scatter plot chart showing percentage difference (%) on the vertical axis versus daily dose (mg) on the horizontal axis for three studies labeled as study a, study b, and study c. The daily doses displayed range from approximately 600 to 1800 mg, with data points marked by different shaped or shaded squares representing each study group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.